ReviewFrontiers in aging neuroscience2019
The Post-amyloid Era in Alzheimer's Disease: Trust Your Gut Feeling.
Review in Frontiers in aging neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Pooled it
- Senescence as a Central Node in Alzheimer's Disease: Molecular Triggers, Cellular Effectors, and RNA-Based Interventions.Neurochemical research · 2026Review
- The role of the oral microbiome, host response, and periodontal disease treatment in Alzheimer's disease: A primer.Periodontology 2000 · 2025Review
- Altered Mitochondrial Morphology and Bioenergetics in a New Yeast Model Expressing Aβ42.International journal of molecular sciences · 2023Article
- Evidence supportive of a bacterial component in the etiology for Alzheimer's disease and for a temporal-spatial development of a pathogenic microbiome in the brain.Frontiers in cellular and infection microbiology · 2023Article
- Virus-Induced Membrane Fusion in Neurodegenerative Disorders.Frontiers in cellular and infection microbiology · 2022Review
- Potential therapeutic effects of boswellic acids/Boswellia serrata extract in the prevention and therapy of type 2 diabetes and Alzheimer's disease.Naunyn-Schmiedeberg's archives of pharmacology · 2021Review
- Astrocyte senescence and SASP in neurodegeneration: tau joins the loop.Cell cycle (Georgetown, Tex.) · 2021Article
- Crosstalk between Gut and Brain in Alzheimer's Disease: The Role of Gut Microbiota Modulation Strategies.Nutrients · 2021Review
- Article
- Infection threat shapes our social instincts.Behavioral ecology and sociobiology · 2021Review
- Broader Insights into Understanding Tumor Necrosis Factor and Neurodegenerative Disease Pathogenesis Infer New Therapeutic Approaches.Journal of Alzheimer's disease : JAD · 2021Review
- Targeting Impaired Antimicrobial Immunity in the Brain for the Treatment of Alzheimer's Disease.Neuropsychiatric disease and treatment · 2021Review
- Endothelial Senescence and Chronic Fatigue Syndrome, a COVID-19 Based Hypothesis.Frontiers in cellular neuroscience · 2021Article
- Relationship between Wine Consumption, Diet and Microbiome Modulation in Alzheimer's Disease.Nutrients · 2020Review
- Motifs and interface amino acid-mediated regulation of amyloid biogenesis in microbes to humans: potential targets for intervention.Biophysical reviews · 2020Review
- WEIRD bodies: mismatch, medicine and missing diversity.Evolution and human behavior : official journal of the Human Behavior and Evolution Society · 2020Article
- Sildenafil for the Treatment of Alzheimer's Disease: A Systematic Review.Journal of Alzheimer's disease reports · 2020Review
- Biomimetic Nanocarrier Targeting Drug(s) to Upstream-Receptor Mechanisms in Dementia: Focusing on Linking Pathogenic Cascades.Biomimetics (Basel, Switzerland) · 2020Review
- Why does the Aβ peptide of Alzheimer share structural similarity with antimicrobial peptides?Communications biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The amyloid hypothesis, the assumption that beta-amyloid toxicity is the primary cause of neuronal and synaptic loss, has been the mainstream research concept in Alzheimer's disease for the past two decades. Currently, this model is quietly being replaced by a more holistic, "systemic disease" paradigm which, like the aging process, affects multiple body tissues and organs, including the gut microbiota. It is well-established that inflammation is a hallmark of cellular senescence; however, the infection-senescence link has been less explored. Microbiota-induced senescence is a gradually emerging concept promoted by the discovery of pathogens and their products in Alzheimer's disease brains associated with senescent neurons, glia, and endothelial cells. Infectious agents have previously been associated with Alzheimer's disease, but the cause vs. effect issue could not be resolved. A recent study may have settled this debate as it shows that gingipain, a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.